Quizartinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Quizartinib
Accession Number
DB12874  (DB05213)
Type
Small Molecule
Groups
Investigational
Description

Quizartinib is under investigation in Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies. It is a potent inhibitor of FLT3.

Structure
Thumb
Synonyms
  • N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea
  • Quizartinib
  • Quizartinibum
External IDs
AC 010220 / AC 220 / AC-010220 / AC-220 / AC010220 / AC220
Categories
UNII
7LA4O6Q0D3
CAS number
950769-58-1
Weight
Average: 560.67
Monoisotopic: 560.220574708
Chemical Formula
C29H32N6O4S
InChI Key
CVWXJKQAOSCOAB-UHFFFAOYSA-N
InChI
InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
IUPAC Name
3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0²,⁶]dodeca-1(8),3,5,9,11-pentaen-4-yl}phenyl)urea
SMILES
CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1

Pharmacology

Indication
Not Available
Pharmacodynamics

In preclinical studies, Quizartinib demonstrated dose-dependent activity and favorable drug-like profiles in bioavailability, pharmacokinetics, cytochrome P450 (CYP) liability, and absorption, distribution, metabolism, excretion (ADME).

Mechanism of action

Quizartinib potently inhibits FLT3, a kinase that is mutated in approximately one-third of acute myeloid leukemia cases, and patients with FLT3 mutations are less responsive to traditional therapies.

TargetActionsOrganism
UReceptor-type tyrosine-protein kinase FLT3Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
24889392
PubChem Substance
347829030
ChemSpider
24640357
BindingDB
50300690
ChEBI
90217
ChEMBL
CHEMBL576982
HET
P30
Wikipedia
Quizartinib
PDB Entries
4rt7 / 4xuf

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)3
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome / Smith-Magenis Syndrome1
1CompletedTreatmentLymphoblastic Leukemia, Acute, Childhood / Myelogenous Leukemia, Acute, Childhood1
1CompletedTreatmentRefractory AML / Relapsed AML1
1CompletedTreatmentTumors, Solid1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1, 2Active Not RecruitingTreatmentAcute, recurrent Myeloid Leukemia / FLT3 Gene Mutation / Leukemias / Recurrent Chronic Myelomonocytic Leukemia / Recurrent Myelodysplastic Syndrome / Refractory Acute Myeloid Leukemia / Refractory Chronic Myelomonocytic Leukemia / Refractory Myelodysplastic Syndrome1
1, 2CompletedTreatmentHigh Risk Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentAcute Myeloid Leukemia With FLT3/ITD Mutation / Acute, recurrent Myeloid Leukemia / Blasts More Than 10 Percent of Bone Marrow Nucleated Cells / Blasts More Than 10 Percent of Peripheral Blood White Cells / Myelodysplastic Syndrome / Recurrent Myelodysplastic Syndrome1
1, 2RecruitingTreatmentAcute Myeloid Leukemia With FLT3/ITD Mutation / Acute, recurrent Myeloid Leukemia / FLT3 Gene Mutation / FLT3 Internal Tandem Duplication / Refractory Acute Leukemia1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)3
2RecruitingTreatmentFLT3-ITD Mutation / Leukemia Acute Myeloid Leukemia (AML)1
3Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias1
Not AvailableAvailableNot AvailableAcute Myeloid Leukemia With Gene Mutations1
Not AvailableCompletedNot AvailableChildhood Acute Myeloid Leukemia/Other Myeloid Malignancies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0509 mg/mLALOGPS
logP5.13ALOGPS
logP5.16ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)10.43ChemAxon
pKa (Strongest Basic)6.62ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area106.16 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity168.24 m3·mol-1ChemAxon
Polarizability61.51 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Phenylimidazoles
Alternative Parents
N-phenylureas / Benzothiazoles / Alkyl aryl ethers / N-substituted imidazoles / Morpholines / Imidolactams / Thiazoles / Heteroaromatic compounds / Isoxazoles / Ureas
show 8 more
Substituents
5-phenylimidazole / 4-phenylimidazole / N-phenylurea / 1,3-benzothiazole / Alkyl aryl ether / Monocyclic benzene moiety / Morpholine / N-substituted imidazole / Oxazinane / Imidolactam
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells...
Gene Name
FLT3
Uniprot ID
P36888
Uniprot Name
Receptor-type tyrosine-protein kinase FLT3
Molecular Weight
112902.51 Da

Drug created on October 20, 2016 18:57 / Updated on June 04, 2019 07:43